News

Filter

Current filters:

XalkoriPfizer

1 to 9 of 15 results

Pfizer and Merck to explore potential of Xalkori/pembrolizumab combo

Pfizer and Merck to explore potential of Xalkori/pembrolizumab combo

26-08-2014

US pharma giants Pfizer and Merck & Co have inked an agreement to explore the therapeutic potential of…

Merck & CoOncologypembrolizumabPfizerPharmaceuticalResearchXalkori

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

Pfizer’s Xalkori meets PFS endpoints in untreated NSCLC patients

25-03-2014

US pharma behemoth Pfizer says that PROFILE 1014, a Phase III study of anaplastic lymphoma kinase (ALK)…

OncologyPfizerPharmaceuticalResearchXalkori

Pfizer’s Xalkori gains regular FDA approval for NSCLC

Pfizer’s Xalkori gains regular FDA approval for NSCLC

22-11-2013

The US Food and Drug Administration yesterday (November 21) granted pharma behemoth Pfizer’s Xalkori…

North AmericaOncologyPfizerPharmaceuticalRegulationXalkori

Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC

04-11-2013

Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…

AstraZenecaEuropeIressaOncologyPfizerPharmaceuticalPricingRegulationRocheTarcevaXalkori

NICE says Xalkori is not cost effective in ALK-positive NSCLC

20-08-2013

US pharma behemoth Pfizer (NYSE: PFE) has today (August 16) expressed concern and disappointment that…

EuropeOncologyPfizerPharmaceuticalPricingRegulationXalkori

1 to 9 of 15 results

Back to top